Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 25/06/20 → 31/12/21 |
Keywords
- Urologic Oncology
- Renal cell carcinoma
- Clinical trial
Clinical Trial Phase
- Phase III (a & b)
A confirmatory, prospective, open-label, multi-centre phase 3 study to evaluate diagnostic performance of 89 Zirconium-labelled girentuximab (89Zr-TLX250) to non-invasively detect clear cell renal cell carcinoma (ccRCC) by positron emission tomography/CT (PET/CT) imaging in patients with indeterminate renal masses [Zr-TLX250-003] [ZIRCON].
- Frydenberg, Mark (Primary Chief Investigator (PCI))
- Baker, Emma (Project Manager)
- Thompson, Katherine (Project Manager)
Project: Research